TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10677890
Drug: Isotonic chlorine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotonic chlorine solution
Study: 1837260
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg etodolac twice daily for 12 weeks
Study: 1837260
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg piroxicam once daily for 12 weeks
Study: 7060822
Drug: 2% miconazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% miconazole nitrate aerosol spray powder
Study: 7060822
Drug: 1% tolnaftate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% tolnaftate aerosol spray powder
Study: 28927706
Drug: Evolocumab (140
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evolocumab (140 mg every 2 weeks or 420 mg once per month)
Study: 25562510
Drug: Functional incidental
Normalized name: plasma protein fraction Injection [Plasmanate]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Functional incidental training (FIT) program consisting of 4 extra episodes of functional exercise daily during SSR
Study: 24673819
Drug: Intravenous silibinin
Normalized name: Silibinin
DrugBank: Silibinin (DB09298)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous silibinin (20 mg/kg daily for 14 days)
Study: 17071000
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy (CBT) for chronic pain, specific details on dosage and duration not available.
Study: 11588683
Drug: Group 1
Normalized name: Chlamydophila psittaci biogroup 1 Ab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 1 (123 ml of 300 mgl/ml)
Study: 11588683
Drug: Group 2
Normalized name: Chlamydophila psittaci biogroup 2 Ab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 2 (112 ml of 335 mgl/ml)
Study: 11588683
Drug: Group 3
Normalized name: Chlamydophila psittaci biogroup 3 Ab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 3 (100 ml of 370 mgl/ml)
Study: 9540151
Drug: 30 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg/kg propacetamol
Study: 9540151
Drug: 0.2 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg/kg morphine
Study: 8022626
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of low-dose morphine (2 mg) and bupivacaine (25 mg)
Study: 8022626
Drug: All treatments
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All treatments (Combination, Bupivacaine, Morphine)
Study: 2645916
Drug: Glucose (1
Normalized name: Fludeoxyglucose (18F)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glucose (1 mg/kg po)
Study: 30882242
Drug: Pro II
Normalized name: Climara Pro
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pro II (a capsule containing 3 strains, 109 cfu per strain)
Study: 30882242
Drug: Pro I
Normalized name: Cipro I.V.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pro I (a capsule containing 3 strains, 109 cfu per strain)
Study: 31152911
Drug: Revefenacin 88
Approvals — FDA: no, EMA: no, PMDA: no
Description: Revefenacin 88 μg
Study: 28987804
Drug: Revefenacin 350
Approvals — FDA: no, EMA: no, PMDA: no
Description: Revefenacin 350 μg
Study: 29096627
Drug: Revefenacin ≥88
Approvals — FDA: no, EMA: no, PMDA: no
Description: Revefenacin ≥88 μg
Study: 21242072
Drug: C. laevigata
Approvals — FDA: no, EMA: no, PMDA: no
Description: C. laevigata (400 mg three times a day)
Study: 20205984
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg isoflavones
Study: 17919059
Drug: Bur treatment
Normalized name: bur oak pollen extract
DrugBank: Quercus macrocarpa pollen (DB10738)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bur treatment (Intensive bur FG 40D4)
Study: 7762909
Drug: Ganciclovir, 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ganciclovir, 2.5 mg/kg body weight administered intravenously on every day that antilymphocyte antibody therapy was administered
Study: 7762909
Drug: No anticytomegalovirus
Approvals — FDA: no, EMA: no, PMDA: no
Description: No anticytomegalovirus therapy
Study: 2306420
Drug: Propranolol 160
Normalized name: propranolol 160 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol 160 mg HCl for 4 days
Study: 30590600
Drug: Uninterrupted (UI)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Uninterrupted (UI) non-vitamin K antagonist oral anticoagulants (NOACs)
Study: 30590600
Drug: Single-dose skipped
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose skipped (SDS) NOACs
Study: 25754330
Drug: Tildrakizumab 3
Normalized name: Tildrakizumab
DrugBank: Tildrakizumab (DB14004)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tildrakizumab 3 mg/kg
Study: 25754330
Drug: Tildrakizumab 10
Normalized name: tildrakizumab 100 mg/mL subcutaneous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tildrakizumab 10 mg/kg
Study: 25754330
Drug: Tildrakizumab 3
Normalized name: Tildrakizumab
DrugBank: Tildrakizumab (DB14004)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tildrakizumab 3 mg/kg and 10 mg/kg (pooled)
Study: 22848074
Drug: Nitroglycerin (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitroglycerin (200 µg via ipsilateral peripheral vein about 3 min before puncture)
Study: 11249725
Drug: BLP-25 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BLP-25 vaccine with IL-2 in a liposomal delivery system
Study: 3481508
Drug: Intra-amniotic PGF2
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-amniotic PGF2 alpha 40 mg followed by oxytocin stimulation
Study: 3481508
Drug: Intracervical PGE2
Normalized name: PGE2
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intracervical PGE2 1.0 mg in gel for 4 h followed by intra-amniotic PGF2 alpha 40 mg
Study: 3481508
Drug: Intracervical PGE2
Normalized name: PGE2
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intracervical PGE2 1.0 mg in gel
Study: 26850877
Drug: Intravenous (IV)
Normalized name: intravenous (IV) infusion pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) dexmedetomidine (1.0 μg/kg)
Study: 26850877
Drug: Intranasal (IN)
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal (IN) dexmedetomidine (1.5 μg/kg)
Study: 18184543
Drug: Western medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Western medicine (WM) therapy including voltaren extended action tablet, methotrexate, and sulfasalazine
Study: 18184543
Drug: Traditional Chinese
Normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional Chinese medicine (CM) therapy including glucosidorum Tripterygll totorum tablet and Yishen Juanbi Tablet
Study: 15250433
Drug: Venlafaxine (maximum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venlafaxine (maximum tolerated dose, 75 mg in most cases)
Study: 9717594
Drug: 5 IU
Normalized name: Vitamin E 15 IU/0.3 ML Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 IU oxytocin i.v. and 2 ml saline imy
Study: 9717594
Drug: 20 IU
Normalized name: Calcium/Phosphorus/Vitamin D 105 MG-81 MG-120 IU Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 IU oxytocin into the myometrium and 0.5 ml saline i.v.
Study: 8628581
Drug: Ketamine (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine (mean dose: 32 mg)
Study: 8628581
Drug: Alfentanil (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfentanil (mean dose: 3075 micrograms)
Study: 2501394
Drug: Mupirocin (Bactroban)
Normalized name: Mupirocin
DrugBank: Mupirocin (DB00410)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mupirocin (Bactroban) ointment applied twice daily for 7 days
Study: 2501394
Drug: Sodium fusidate
Normalized name: Sodium fusidate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium fusidate (Fucidin) ointment applied thrice daily for 7 days
Study: 353089
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg phenobarbital plus 8 mg belladonna (P & B)
Study: 31676719
Drug: Home-based care
Normalized name: Gelato Home-Care 1.1 % Toothpaste
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home-based care from patient-nominated lay people trained to deliver intramuscular streptomycin.
Study: 24706006
Drug: Methotrexate (initial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methotrexate (initial treatment), followed by either sulfasalazine+hydroxychloroquine or infliximab for non-responders.
Study: 21785396
Drug: Budesonide 0.25
Normalized name: budesonide 0.25 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide 0.25 mg/g cream in the morning and tacalcitol 4 µg/g ointment in the evening
Study: 21785396
Drug: Calcipotriol 50
Normalized name: Calcipotriol 50 microgram/g cutaneous cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcipotriol 50 µg/g plus betamethasone dipropionate 0.5 mg/g ointment once daily
Study: 26669417
Drug: Music therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Music therapy (20 minutes)
Study: 16699359
Drug: Music therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Music therapy and Control
Study: 15567701
Drug: Heavy derivative
Normalized name: heavy mineral oil
DrugBank: Mineral oil (DB11057)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heavy derivative PD control approach for insulin infusion
Study: 15567701
Drug: Modelled insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Modelled insulin infused
Study: 11699800
Drug: Immediate-release dextroamphetamine
Normalized name: dextroamphetamine Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate-release dextroamphetamine sulfate
Study: 11699800
Drug: Immediate-release amphetamines
Normalized name: amphetamine Extended Release Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate-release amphetamines
Study: 7624642
Drug: Conventional fractionated
Normalized name: LIVER FRACTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional fractionated radiation therapy (20 and 45 Gy delivered in 10 and 15 fractions)
Study: 7624642
Drug: Conventional fractionated
Normalized name: LIVER FRACTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional fractionated radiation therapy
Study: 3688637
Drug: Indomethacin (Indocin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin (Indocin SR 75 mg every 12 h for 5 days)
Study: 28401441
Drug: Inpatient multicomponent
Normalized name: Impatiens irvingii whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inpatient multicomponent occupational rehabilitation (4+4 days) including Acceptance and Commitment Therapy (ACT), physical training, and work-related problem-solving.
Study: 1478163
Drug: Macrocrystalline nitrofurantoin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Macrocrystalline nitrofurantoin 50 mg
Study: 22877506
Drug: Prophylactic platelet
Normalized name: platelet glycoprotein VI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic platelet transfusion strategy (transfusion when platelet counts were 10×10(9) per L or lower)
Study: 3307717
Drug: Topical 1%
Normalized name: fluoride topical 1% topical gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 1% ALO 2145 (p‐aminoclonidine hydrochloride)
Study: 31201057
Drug: Automated reminder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Automated reminder to recommend the 2nd or 3rd dose of HPV vaccine
Study: 26054139
Drug: Medication group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication group (basic treatment combined with oral administration of regular antidiabetics)
Study: 19916293
Drug: Comparison between
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison between acupuncture and medication groups
Study: 9246043
Drug: IFN 3
Normalized name: IFNγ
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFN 3 MU three times a week + UDCA 250 mg twice a day
Study: 9246043
Drug: UDCA alone
Normalized name: UDCA
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: UDCA alone 250 mg twice a day
Study: 3326393
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg oral PGE2 given hourly for two 12-h periods
Study: 3326393
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of PGE2 priming and induction of labor with oxytocin
Study: 22317756
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D (25 μg/d as cholecalciferol)
Study: 20075050
Drug: Pre- and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre- and post-bronchodilator spirometry or a single bronchial challenge test
Study: 20075050
Drug: Tapering of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tapering of asthma medications and repeated bronchial challenge tests
Study: 9613362
Drug: Gulliver (G)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gulliver (G)
Study: 9613362
Drug: Gulliver (G)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gulliver (G) and Book/Tape Method (TM)
Study: 7992933
Drug: Amoxicillin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin (1 g intravenous injection immediately after induction of anaesthesia, followed by postoperative injections every 6 hours for 36 hours, total of 6 injections)
Study: 7992933
Drug: Cefamandole (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefamandole (1.5 g intravenous injection immediately after induction of anaesthesia, followed by postoperative injections every 6 hours for 36 hours, total of 6 injections)
Study: 26707087
Drug: .20 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: .20 mg/kg esketamine
Study: 26707087
Drug: .40 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: .40 mg/kg esketamine
Study: 24883300
Drug: 0.30 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.30 mg/kg rectal midazolam diluted with 5 mL saline (Group M)
Study: 24883300
Drug: 5 mL
Normalized name: WATER,INHL 5 ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mL saline (Group C)
Study: 22467361
Drug: Resource-oriented cognitive-behavioral
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resource-oriented cognitive-behavioral therapy (ROCBT)
Study: 20554904
Drug: Oral sea
Normalized name: Deep Sea
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral sea buckthorn (SB) oil, 2 g daily for 3 months
Study: 20554904
Drug: Placebo oil,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo oil, 2 g daily for 3 months
Study: 20554904
Drug: Oral sea
Normalized name: Deep Sea
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral sea buckthorn (SB) oil
Study: 15750155
Drug: Biphasic injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biphasic injection (90 and 50 mL at 3 and 1.5 mL/s) of intravenous contrast (300 mg/mL iodine)
Study: 15750155
Drug: Triple-phase injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple-phase injection (90, 40, and 40 mL at 3, 2, and 1.5 mL/s)
Study: 15750155
Drug: Dual-phase injection
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual-phase injection (80 and 60 mL at 3 and 1.5 mL/s) in the caudocranial direction with a 50-s delay
Study: 15750155
Drug: No intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: No intravenous contrast agent
Study: 10989865
Drug: Ketamine 5
Normalized name: ketamine 50 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine 5 mg iv
Study: 10989865
Drug: Saline 2
Normalized name: SODIUM CHLORIDE BRONCHO-SALINE 240ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline 2 ml iv
Study: 1424430
Drug: l-methylphenidate
Approvals — FDA: no, EMA: no, PMDA: no
Description: l-methylphenidate
Study: 22726401
Drug: Beta-blocker titration
Normalized name: interferon beta-1a
DrugBank: Interferon beta-1a (DB00060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Beta-blocker titration
Study: 11696811
Drug: Alarm therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alarm therapy combined with 40 microg intranasal desmopressin for 3 weeks followed by 20 microg desmopressin for 3 weeks (group 1)
Study: 11696811
Drug: Alarm therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alarm therapy and placebo (group 2)
Study: 11696811
Drug: Both treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatment modalities (group 1 and group 2)
Study: 9216706
Drug: Systemic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic therapy plus radiotherapy (Arm B)
Study: 9216706
Drug: Systemic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic therapy alone (Arm A)
Study: 2213264
Drug: Tocolysis and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tocolysis and prophylactic antibiotic administration
Study: 2213264
Drug: Other antibiotics
Normalized name: Other antibiotics for topical use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other antibiotics (cefoxitin, cefazolin, ampicillin)
Study: 30149148
Drug: G‐CSF +
Approvals — FDA: no, EMA: no, PMDA: no
Description: G‐CSF + plerixafor
Study: 9216955
Drug: Melatonin (Mel)
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Melatonin (Mel) 5 mg po administered at 1300
Study: 7970472
Drug: Intrapartum intrathecal
Normalized name: beractant
DrugBank: Beractant (DB06761)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intrapartum intrathecal narcotic analgesia (25 micrograms fentanyl and 0.25 mg morphine sulfate)
Study: 3313684
Drug: Relaxation therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Relaxation therapy for 6 months
Study: 19832996
Drug: Collaborative care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Collaborative care (case manager coordinated support and brief psychological treatment, enhanced specialist and GP communication)
Study: 11318768
Drug: Allopurinol (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allopurinol (300 mg daily if creatinine < 150 micromol l‐1 or 100 mg if creatinine > 150 micromol l‐1)
Study: 10481379
Drug: Euthyroidism after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Euthyroidism after surgical treatment
Study: 6373102
Drug: Prochlorperazine (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prochlorperazine (6 mg/sq m)
Study: 6373102
Drug: Haloperidol (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol (1 mg/sq m)
Study: 6373102
Drug: Droperidol (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Droperidol (1 mg/sq m)
Study: 31834923
Drug: Telephone administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Telephone administration of the Patient-Specific Functional Scale (PSFS)
Study: 31834923
Drug: In-person administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: In-person administration of the Patient-Specific Functional Scale (PSFS)
Study: 29743962
Drug: Fentanyl (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl (50 mg)
Study: 19750873
Drug: Prismatic displacement
Normalized name: ZINC OXIDE 132 mg in 1 mL TOPICAL LOTION [Volition Prismatic Luminizing Shield]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prismatic displacement adaptation with a concurrent cognitive task (serial subtractions of 7)
Study: 19750873
Drug: Prismatic displacement
Normalized name: ZINC OXIDE 132 mg in 1 mL TOPICAL LOTION [Volition Prismatic Luminizing Shield]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prismatic displacement adaptation with a concurrent cognitive task (repeating back tones)
Study: 19750873
Drug: Prismatic displacement
Normalized name: ZINC OXIDE 132 mg in 1 mL TOPICAL LOTION [Volition Prismatic Luminizing Shield]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prismatic displacement adaptation without a concurrent cognitive task
Study: 17578562
Drug: 17OHPC (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: 17OHPC (250 mg intramuscular injections weekly from 16-20 weeks up to 36 weeks)
Study: 1850282
Drug: Balanced Saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Balanced Saline Solution Plus (BSS Plus)
Study: 29024419
Drug: EpiFix and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: EpiFix and multilayer compression therapy
Study: 29024419
Drug: Standard wound
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard wound care and multilayer compression therapy
Study: 27588078
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment + oral administration of Jiawei Di Tan Tang
Study: 22568808
Drug: Roledumab (30-3000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Roledumab (30-3000 μg i.v. and 300 μg i.m.)
Study: 22568808
Drug: Roledumab (30-3000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Roledumab (30-3000 μg i.v.)
Study: 22568808
Drug: Roledumab (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Roledumab (300 μg i.m.)
Study: 11932063
Drug: PCA morphine
Normalized name: lauryl PCA
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCA morphine 1 mg/cc plus naloxone 6 microg/cc
Study: 11932063
Drug: PCA morphine
Normalized name: lauryl PCA
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCA morphine 1 mg/cc plus normal saline
Study: 8154643
Drug: Ceftazidime (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftazidime (2 g every 8 h)
Study: 8154643
Drug: Piperacillin (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piperacillin (12 to 18 g/d in 4 to 6 divided doses) plus Tobramycin (1.7 to 2.0 mg/kg body weight every 8 h)
Study: 2830091
Drug: Enalapril 5
Normalized name: enalapril 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril 5 mg twice a day
Study: 31832821
Drug: Eribulin mesylate
Normalized name: Eribulin Mesylate
DrugBank: Eribulin (DB08871)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Eribulin mesylate (1.4 mg/m2 on days 1 and 8 every 21 days)
Study: 31832821
Drug: Vinorelbine (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vinorelbine (25 mg/m2 on days 1, 8, and 15 every 21 days)
Study: 16774980
Drug: Warfarin (target
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin (target INR 2.0-3.0)
Study: 29122636
Drug: Apixaban vs
Normalized name: Apixaban
DrugBank: Apixaban (DB06605)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Apixaban vs Warfarin
Study: 20934155
Drug: Intermittent administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intermittent administration of tisokinase (960,000 IU)